Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4331 Amino acid-induced hyperkalaemia during peptide receptor radionuclide therapy (PRRT): A case report and literature review

Introduction: PRRT an established treatment for neuroendocrine tumours (NETs). Therapy requires prophylactic positively charged amino acid (AA) co-infusion to reduce renal radiation exposure. AA infusion has been associated with metabolic acidosis and electrolyte abnormalities, particularly hyperkalaemia; comprehensive data on the prevalence and severity of these complications remains limited.

Conference:

Presenting Author:

Authors: Osher E, Wolf I, Geva R, Sofer Y, Greenman Y,

Keywords: PRRT, hyperkalaemia, amino acid infusion, neuroendocrine tumour, adverse effects,

#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC

Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Mottaghy F,

Keywords: PRRT, 90y-DOTATOC, dosimetry, 111in-octreotide, amino acids,

#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors

Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Roether M, Zachert C, Baum R,

Keywords: Peptide Receptor Radionuclide Therapy (PRRT), low dose multiple cycle, well-differentiated neuroendocrine tumors,

#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs

Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Prasad V, Budiawan H, Ali S, Hoersch D, Zachert C,

Keywords: Peptide Receptor Radionuclide Therapy (PRRT), thyroid cancer, survival, toxicity, response,